---
title: "SIMCERE PHARMA: The new drug application (NDA) for Maribavir granules has been accepted by the National Medical Products Administration"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/255758153.md"
description: "SIMCERE PHARMA's new drug application (NDA) for the anti-influenza drug Madaxanovir granules, in collaboration with Jiaxing Andikang Biotechnology Co., Ltd., has been accepted by the National Medical Products Administration. This drug is used to treat uncomplicated influenza A and B in children aged 2 to 11 years and is China's first innovative antiviral drug for children, with good safety and multiple clinical advantages"
datetime: "2025-09-03T10:05:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255758153.md)
  - [en](https://longbridge.com/en/news/255758153.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255758153.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/255758153.md) | [繁體中文](https://longbridge.com/zh-HK/news/255758153.md)


# SIMCERE PHARMA: The new drug application (NDA) for Maribavir granules has been accepted by the National Medical Products Administration

According to the Zhitong Finance APP, SIMCERE PHARMA (02096) announced that on September 3, 2025, the new drug application (NDA) for the anti-influenza drug Madaxinosawei granules (Xianlinda®), developed in collaboration with Jiaxing Andikang Biotechnology Co., Ltd. (Andikang), was accepted by the National Medical Products Administration (NMPA). This drug is intended for the treatment of uncomplicated type A and type B influenza in children aged 2 to 11 years and is the first innovative antiviral drug targeting pediatric patients in China to successfully complete Phase III clinical trials and apply for market approval.

Madaxinosawei is a cap-dependent endonuclease inhibitor. Its mechanism of action involves inhibiting the cap-dependent endonuclease essential for influenza virus replication, thereby blocking the transcription of the virus's own mRNA and precisely suppressing viral replication.

Clinical studies have shown that Madaxinosawei granules have good safety in pediatric patients, faster symptom relief and viral clearance, lower risk of resistance, oral efficacy unaffected by food, and a formulation more suitable for pediatric patients, among other potential clinical advantages

### 相关股票

- [SIMCERE PHARMA (02096.HK)](https://longbridge.com/zh-CN/quote/02096.HK.md)

## 相关资讯与研究

- [Simcere Pharmaceutical Presents Bladder Cancer Drug Trial Results at European Urology Conference](https://longbridge.com/zh-CN/news/279439171.md)
- [Ubtech Robotics Narrows Loss in 2025](https://longbridge.com/zh-CN/news/281187944.md)
- [PetroChina Renews Financial Deal With Related Company](https://longbridge.com/zh-CN/news/280998322.md)
- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-CN/news/281054154.md)
- [Wuxi Lead Intelligent Equipment FY net profit amounted to RMB1,559.8 million](https://longbridge.com/zh-CN/news/281053550.md)